Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia

American Journal of Hematology

Volumn 90, Issue 2, 2015, Pages 120-124

  Kadia, Tapan M ^a   Kantarjian, Hagop M ^a   Thomas, Deborah A ^a   O'Brien, Susan ^a   Estrov, Zeev ^a   Ravandi, Farhad ^a   Jabbour, Elias ^a   Pemmaraju, Naveen ^a   Daver, Naval ^a   Wang, Xuemei ^a   Jain, Preetesh ^a   Pierce, Sherry ^a   Brandt, Mark ^a   Garcia Manero, Guillermo ^a   Cortes, Jorge ^a   Borthakur, Gautam ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; AMYLASE; ASPARAGINASE MACROGOL; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CD20 ANTIGEN; DASATINIB; DEXAMETHASONE; FIBRINOGEN; IMATINIB; METHOTREXATE; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB; TRIACYLGLYCEROL LIPASE; VINCRISTINE; ANTINEOPLASTIC AGENT; ASPARAGINASE; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; B CELL LEUKEMIA; BACTERIAL INFECTION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERGLYCEMIA; INFECTION; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYCOSIS; NAUSEA; OSTEOMYELITIS; PANCREATITIS; PERIANAL ABSCESS; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PHILADELPHIA CHROMOSOME POSITIVE CELL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; SIDE EFFECT; T CELL LEUKEMIA; THROMBOSIS; TREATMENT RESPONSE; VIRUS INFECTION; VOMITING; B LYMPHOCYTE; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; MIDDLE AGED; MORTALITY; PATHOLOGY; PILOT STUDY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENT DISEASE; SURVIVAL; T LYMPHOCYTE; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; B-LYMPHOCYTES; BILIRUBIN; DEXAMETHASONE; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PILOT PROJECTS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; RECURRENCE; RITUXIMAB; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TRANSAMINASES; TREATMENT OUTCOME; VINCRISTINE;

EID: 84921405793     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23886     Document Type: Article

References (28)

1. Faderl S, O'Brien S, Pui CH, et al. Adult acute lymphoblastic leukemia: Concepts and strategies. Cancer 2010;116:1165-1176.
2. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet 2008;371:1030-1043.
3. Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood 2007;109:944-950.
4. Tavernier E, Boiron JM, Huguet F, et al. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia 2007;21:1907-1914.
5. Thomas DA, Kantarjian H, Smith TL, et al. Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer 1999;86:1216-1230.
6. O'Brien S, Thomas D, Ravandi F, et al. Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer 2008;113:3186-3191.
7. Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 2006;106:1569-1580.
8. Ravandi F, O'Brien S, Thomas D, et al. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood 2010;116:2070-2077.
9. Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004;103:4396-4407.
10. Pui CH, Mullighan CG, Evans WE, et al. Pediatric acute lymphoblastic leukemia: Where are we going and how do we get there? Blood 2012;120:1165-1174.
11. Rytting M. Peg-asparaginase for acute lymphoblastic leukemia. Expert Opin Biol Ther 2010;10:833-839.
12. Capizzi RL. Schedule-dependent synergism and antagonism between methotrexate and asparaginase. Biochem Pharmacol 1974;23:151-161.
13. Capizzi RL. Asparaginase-methotrexate in combination chemotherapy: Schedule-dependent differential effects on normal versus neoplastic cells. Cancer Treat Rep 1981;65(Suppl 4):115-121.
14. Sur P, Fernandes DJ, Kute TE, et al. l-asparaginase-induced modulation of methotrexate polyglutamylation in murine leukemia L5178Y. Cancer Res 1987;47:1313-1318.
15. Vadlamudi S, Krishna B, Reddy VV, et al. Schedule-dependent therapeutic synergism for l-asparaginase and methotrexate in leukemic (L5178Y) mice. Cancer Res 1973;33:2014-2019.
16. Jolivet J, Cole DE, Holcenberg JS, et al. Prevention of methotrexate cytotoxicity by asparaginase inhibition of methotrexate polyglutamate formation. Cancer Res 1985;45:217-220.
17. Lobel JS, O'Brien RT, McIntosh S, et al. Methotrexate and asparaginase combination chemotherapy in refractory acute lymphoblastic leukemia of childhood. Cancer 1979;43:1089-1094.
18. Wiernik PH, Dutcher JP, Paietta E, et al. Long-term follow-up of treatment and potential cure of adult acute lymphocytic leukemia with MOAD: A non-anthracycline containing regimen. Leukemia 1993;7:1236-1241.
19. van den Berg H. Asparaginase revisited. Leuk Lymphoma 2011;52:168-178.
20. Wetzler M, Sanford BL, Kurtzberg J, et al. Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511. Blood 2007;109:4164-4167.
21. Thall PF, Simon RM, Estey EH. New statistical strategy for monitoring safety and efficacy in single-arm clinical trials. J Clin Oncol 1996;14:296-303.
22. Aguayo A, Cortes J, Thomas D, et al. Combination therapy with methotrexate, vincristine, polyethylene-glycol conjugated-asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia. Cancer 1999;86:1203-1209.
23. Bostrom BC, Sensel MR, Sather HN, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 2003;101:3809-3817.
24. Ito C, Evans WE, McNinch L, et al. Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. J Clin Oncol 1996;14:2370-2376.
25. Jones B, Freeman AI, Shuster JJ, et al. Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia. Med Pediatr Oncol 1991;19:269-275.
26. Kaspers GJ, Veerman AJ, Popp-Snijders C, et al. Comparison of the antileukemic activity in vitro of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. Med Pediatr Oncol 1996;27:114-121.
27. Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 2001;97:1211-1218.
28. Larson RA, Fretzin MH, Dodge RK, et al. Hypersensitivity reactions to l-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia. Leukemia 1998;12:660-665.